Bilateral neuroretinitis and anterior uveitis following ipilimumab treatment for metastatic melanoma

Journal of Ophthalmic Inflammation and Infection

Volumn 6, Issue 1, 2016, Pages

  Hahn, Laura ^a   Pepple, Kathryn L ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Ipilimumab; Neuroretinitis; Uveitis

Indexed keywords

BRIMONIDINE; DIFLUPREDNATE; IPILIMUMAB; PREDNISOLONE ACETATE; PREDNISONE; TIMOLOL MALEATE;

ABSCESS; ADULT; ARTERIOVENOUS FISTULA; ARTICLE; BILATERAL NEURORETINITIS; CASE REPORT; CONVALESCENCE; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DRUG MEGADOSE; DRUG WITHDRAWAL; EYE INFLAMMATION; FEVER; HUMAN; IRIDOCYCLITIS; MACULAR EDEMA; MALE; MEDICAL RECORD REVIEW; METASTATIC MELANOMA; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; RASH; RECTAL ABSCESS; RETINA FOLD; RETINITIS; SLIT LAMP; VISUAL ACUITY;

EID: 84971222304     PISSN: None     EISSN: 18695760     Source Type: Journal    
DOI: 10.1186/s12348-016-0082-3     Document Type: Article

References (16)

1. Leach DR, Krummel MF, Allison JP (1996) Enhancement of antitumor immunity by CTLA-4 blockade. Science 271(5256):1734–6
2. Fong L, Small EJ (2008) Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol 26:5275–5283
3. Fecher LA, Agarwala SS, Hodi SF, Weber JS (2013) Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist 18(6):733–743
4. Weber JS, Kahler KC, Hauschild A (2012) Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30:2691–2697
5. Robinson MR, Chan CC, Yang JC et al (2004) Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. J Immunother 27:478–479
6. Sanderson K, Scotland R, Lee P et al (2005) Autoimmunity in a phase I trial of a fully human anti cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. Clin Oncol 23:741–750
7. Papavaileiou E, Prasad S, Freitag SK, Sobrin L, Lobo A (2015) Ipilimumab-induced ocular and orbital inflammation—a case series and review of the literature. Ocul Immunol Inflamm. doi:10.3109/09273948.2014.1001858
8. Wong RK, Lee JK, Huang JJ (2012) Bilateral drug (ipilimumab)-induced vitritis, choroiditis, and serous retinal detachments suggestive of Vogt-Koyanagi-Harada syndrome. Retin Cases Brief Rep 6(4):423–6
9. Crosson JN, Laird PW, Debiec M, Bergstron CS, Lawson DH, Yeh S (2015) Vogt-Koyanagi-Harada-like syndrome after CTLA-4 inhibition with ipilimumab for metastatic melanoma. J Immunother 38(2):80–84
10. Mantopoulos D, Kendra KL, Letson AD, Cebulla CM (2015) Bilateral choroidopathy and serous retinal detachments during ipilimumab treatment for cutaneous melanoma. JAMA Ophthalmol 133(8):965–7
11. Sheldon CA, Kharlip J, Tamhankar MA (2015) Inflammatory orbitopathy associated with ipilimumab. Ophthal Plast Reconst Surg 10:1097
12. McElnea E, Mhéalóid AN, Moran S, Kelly R, Fulcher T (2014) Thyroid-like ophthalmology in a euthyroid patient receiving ipilimumab. Orbit 33(6):424–427
13. Modjtahedi BS, Maibach H, Park S (2013) Multifocal bilateral choroidal neovascularization in a patient on ipilimumab for metastatic melanoma. Cutan Ocul Toxicol 32(4):341–3
14. Liao B, Shroff S, Kamiya-Matsuoka C, Tummala S (2014) Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol 16(4):589–93
15. Yeh OL, Francis CE (2015) Ipilimumab-associated bilateral optic neuropathy. J Neuro-Ophthalmol 35:144–147
16. Voskens CJ et al (2013) The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One 8(1):e53745